|  Keyword Search
| Date | Title | | | 12/14/05 | Nastech Presents New Methods for Peptide and Protein Drug Delivery at The American Society for Cell Biology Annual Meeting| Research Supports a Role for Endothelial Tight Junctions in Atherosclerosis
and Suggests New Therapeutic Targets for Cardiovascular Disease
BOTHELL, Wash., Dec. 14 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK), a leader in developing therapeutics using
advanced molecular biology-based drug delivery technologies, today announced
the presentation of data from the Company's transmucosal peptide and protein
drug delivery program at The American Society for C... |
|  | | 11/17/05 | Nastech Presents Positive Results on RNA Interference Program for Treatment of Rheumatoid Arthritis at the American College of Rheumatology Annual Scientific Meeting| BOTHELL, Wash., Nov. 17 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK), a leader in developing therapeutics using
advanced molecular biology-based drug delivery technologies, announced the
presentation of data from its RNA interference (RNAi) therapeutic program for
rheumatoid arthritis at the American College of Rheumatology Annual Scientific
Meeting.
The presentation titled "Development of siRNAs Targeting Human Tumor
Necrosis Factor Alpha (TNF-alph... |
| | | 11/14/05 | Nastech Added to NASDAQ Biotechnology Index| BOTHELL, Wash., Nov. 14 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK), a leader in developing therapeutics using
advanced molecular biology-based drug delivery technologies, announced today
that it has been selected for addition to the NASDAQ Biotechnology Index(R)
(Nasdaq: NBI) effective Monday, November 21, 2005. All securities in the Index
are listed on the NASDAQ National Market and must meet certain eligibility
criteria, including market value, avera... |
| | | 11/07/05 | Nastech to Present at CIBC World Markets Healthcare Conference| BOTHELL, Wash., Nov. 7 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK), a leader in developing therapeutics that utilize
proprietary molecular biology-based drug delivery technologies, will be
presenting at the CIBC World Markets Healthcare Conference on Wednesday,
November 9, 2005 at 3:00 p.m. Eastern Time at the Waldorf-Astoria in New York
City. Gordon Brandt, M.D., Executive Vice President, Clinical Research and
Medical Affairs of Nastech, will provide ... |
| | | 11/02/05 | Nastech Announces Third Quarter 2005 Financial Results| BOTHELL, Wash., Nov. 2 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK), a leader in developing therapeutics using
advanced molecular biology-based drug delivery technologies, today reported
financial results for the three- and nine-month periods ended September 30,
2005.
Revenue for the three months ended September 30, 2005 was $1.2 million,
compared to revenue of $0.2 million for the three months ended September 30,
2004. Revenue for the first nine m... |
| | | 10/25/05 | Nastech to Release Third Quarter Financial Results and Host Webcast on Wednesday, November 2, 2005| BOTHELL, Wash., Oct. 25 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK), a leader in developing therapeutics using
advanced molecular biology-based drug delivery technologies, announced today
that its third quarter financial results will be released on Wednesday,
November 2, 2005 after the Nasdaq National Market System closes. Management
will host a conference call with investors and financial analysts to discuss
these results and to provide an update to it... |
| | | 10/17/05 | Nastech to Manufacture Nascobal(R) Nasal Spray for QOL Medical| BOTHELL, Wash., Oct. 17 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK), a leader in developing therapeutics using
advanced molecular biology-based drug delivery technologies, announced today
that, following QOL Medical LLC's acquisition of Nascobal(R) (Cyanocobalamin,
USP) Nasal Spray for the treatment of vitamin B-12 deficiency from Questcor
Pharmaceuticals, Inc. (Amex: QSC), Nastech will be the exclusive manufacturer
of the product for QOL Medical.
... |
| | | 10/17/05 | Nastech Initiates Development Program for Rapid-Acting Intranasal Insulin for Treatment of Diabetes| BOTHELL, Wash., Oct. 17 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK), a leader in developing therapeutics using
advanced molecular biology-based drug delivery technologies, announces today
the initiation of a development program for a proprietary intranasal
formulation of rapid-acting insulin.
The formulation is being developed using Nastech's formulation science
expertise and high-throughput human tissue culture screening process, a
proprietary sys... |
| | | 09/29/05 | Nastech Announces Positive Phase I Pharmacokinetic Study Results of Intranasal Parathyroid Hormone (PTH1-34) for Osteoporosis| BOTHELL, Wash., Sept. 29 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK), a leader in developing therapeutics using
advanced molecular biology-based drug delivery technologies, announced today
positive results from a Phase I pharmacokinetic study of intranasal
Parathyroid Hormone (PTH1-34). The objectives of the study were to determine
the nasal absorption and safety of Nastech's PTH1-34 nasal spray versus the
approved subcutaneous product, Forteo(R) (teri... |
| | | 09/27/05 | Nastech to Present at UBS Global Life Sciences Conference| BOTHELL, Wash., Sept 27, 2005 /PRNewswire-FirstCall via COMTEX News Network/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK), a leader in developing therapeutics that utilize
proprietary molecular biology-based drug delivery technologies, will be
presenting at the UBS Global Life Sciences Conference on Thursday, September
29, 2005 at 11:30 a.m. Eastern Time at the Grand Hyatt New York in New York
City. Gordon Brandt, M.D., Executive Vice President, Clinical Research and
Medical Affa... |
| | | 09/20/05 | Nastech Announces Publication Demonstrating Lower Weight in Preclinical Model Following PYY3-36 Administration| BOTHELL, Wash., Sept. 20 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK), a leader in developing therapeutics that utilize
proprietary molecular biology-based drug delivery technologies, today
announced the publication of preclinical results relating to the
administration of PYY in the International Journal of Obesity.
The peer-reviewed paper, titled "Lower mean weight after 14 days
intravenous administration peptide YY3-36 (PYY3-36) in rabbits," appear... |
| | | 09/15/05 | Nastech to Present at Merriman Curhan Ford & Co. Investor Summit and at the Northwest Medical Device and Biotechnology Investor Forum| BOTHELL, Wash., Sept. 15 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK), a leader in molecular biology-based drug delivery
technologies, will be presenting at two conferences on Tuesday, September 20,
2005. Steven C. Quay, M.D., Ph.D., Chairman, President and Chief Executive
Officer of Nastech, will be presenting at the Merriman Curhan Ford & Co.
Investor Summit at 11:15 a.m. Pacific Time at the InterContinental Mark
Hopkins Hotel in San Francisco. Gordon Bran... |
| | | 09/08/05 | Nastech Pharmaceutical Company Announces Management Change| BOTHELL, Wash., Sept. 8 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK), a leader in molecular biology-based drug delivery
products and technologies, today announced that Gregory Weaver, Chief
Financial Officer, has resigned to pursue other opportunities. Philip Ranker,
currently Vice President of Finance for Nastech, will serve as interim Chief
Financial Officer and Corporate Secretary, effective immediately.
"We thank Greg for his commitment and valuab... |
| | | 08/25/05 | Nastech Announces Pricing of Common Stock Offering| BOTHELL, Wash., Aug. 25 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) today announced the pricing of an underwritten
public offering of 1,725,000 shares of its common stock at a price of $13.50
per share. The gross proceeds of the offering are expected to be
approximately $23.3 million before deducting underwriting discounts and
commission and offering expenses. The offering is being made from a shelf
registration statement that became effective on October ... |
| | | 08/05/05 | Nastech Withdraws Public Offering of Common Stock| BOTHELL, Wash., Aug 05, 2005 /PRNewswire-FirstCall via COMTEX/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) announced today that it has withdrawn its
previously announced public offering of 1.5 million shares of common stock
under its shelf registration statement.
"We appreciate the interest shown by the investment community in Nastech
as we continue to make progress in our research and clinical programs," said
Steven C. Quay, M.D., Ph.D., Chairman, President and CEO of Nastec... |
| | | 08/01/05 | Nastech Announces Proposed Public Offering of Common Stock| BOTHELL, Wash., Aug. 1 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. ("Nastech") (Nasdaq: NSTK) announced today plans to offer
1.5 million shares of common stock in an underwritten public offering pursuant
to an effective shelf registration statement. Nastech intends to grant the
underwriters an option to purchase an additional 225,000 shares of common
stock to cover over-allotments.
Needham & Company, LLC is acting as sole lead book-running manager for the
proposed... |
| | | 08/01/05 | Nastech Announces Second Quarter 2005 Financial Results| BOTHELL, Wash., Aug. 1 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK), a leader in molecular biology-based drug delivery
technologies, today reported financial results for the three- and six-month
periods ended June 30, 2005.
Revenue for the three months ended June 30, 2005 was $1.6 million,
compared to revenue of $45,000 for the three months ended June 30, 2004.
Revenue for the first six months of 2005 was $4.9 million, compared to
$193,000 in the firs... |
| | | 07/25/05 | Nastech to Release Second Quarter Financial Results and Host Webcast on Monday, August 1, 2005| BOTHELL, Wash., July 25 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK), a leader in molecular biology-based drug delivery
technologies, announced today that its second quarter financial results will
be released on Monday, August 1, 2005 after the Nasdaq National Market System
closes. Management will host a conference call with investors and financial
analysts to discuss these results and to provide an update to its clinical
pipeline at 4:30 p.m. Eastern Time (... |
| | | 07/20/05 | Alnylam Grants Nastech a License to Develop RNAi Therapeutics Against TNF-alpha| License For RNAi Intellectual Property Granted Under Alnylam InterfeRx(TM)
Program
CAMBRIDGE, Mass. and BOTHELL, Wash., July 20 /PRNewswire-FirstCall/ --
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics
company, announced today that it has granted Nastech Pharmaceutical Company
Inc. (Nasdaq: NSTK), a leader in molecular biology-based drug delivery
technologies, an exclusive InterfeRx(TM) license to discover, develop, and
co... |
| | | 07/07/05 | Nastech CEO Announces Plan To Exercise Expiring Options| BOTHELL, Wash., July 7 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) today reported that Dr. Steven C. Quay, Chairman,
President and Chief Executive Officer, has filed a Form 144 with the SEC
stating his intention to exercise and hold or sell Nastech stock options
scheduled to expire in August 2005. Dr. Quay intends to use any proceeds from
this transaction to satisfy personal family obligations as well as the
consideration due to Nastech arising from the sto... |
| | | 07/05/05 | Nastech Initiates Phase 1 Clinical Trial for Intranasal Parathyroid Hormone (PTH1-34)| BOTHELL, Wash., July 5 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK), a leader in molecular biology-based drug delivery
technologies, today announced that the Company has commenced a Phase 1
pharmacokinetic study with its intranasal Parathyroid Hormone (PTH1-34) to
treat osteoporosis. The study will be conducted using the Company's advanced
intranasal formulation that utilizes its Tight Junction drug delivery
technology to enable needle-free delivery of ther... |
| | | 07/01/05 | Nastech Pharmaceutical Company Inc. Added to Russell 3000(R) Index| BOTHELL, Wash., July 1 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK), a leader in molecular biology-based drug delivery
products and technologies, today announced that the Company has been added to
the Russell 3000(R) Index. The Russell 3000 Index offers investors access to
the broad U.S. equity universe representing the 3,000 largest U.S. companies
based on total market capitalization. The Russell 3000 is constructed to
provide a comprehensive, unbiased, a... |
| | | 06/23/05 | Nastech to Host 2005 Analyst and Institutional Investor Day| BOTHELL, Wash., June 23 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) will be hosting an analyst and institutional
investor day in New York City on Tuesday, June 28, 2005 from 12:00 p.m. - 3:00
p.m. Eastern Time at the University Club, on One West 54th Street in New York
City. The event will feature presentations from Steven C. Quay, M.D., Ph.D.,
Chairman, President, and CEO of Nastech as well as the following leading
scientific experts:
* Dr. Black... |
| | | 06/17/05 | Nastech to Participate in Panel Session at BIO 2005 Annual International Convention to Discuss the Regulatory Environment for Obesity Therapeutics| BOTHELL, Wash., June 17, 2005 /PRNewswire-FirstCall via COMTEX/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK), a leader in molecular biology-based drug delivery
technologies, today announced that Steven C. Quay, M.D., Ph.D., Chairman,
President and Chief Executive Officer of Nastech, will participate in a panel
entitled, "Changing Regulatory Environment for Anti-Obesity Drug Development,"
at the BIO 2005 Annual International Convention taking place in Philadelphia,
PA from June 19 ... |
| | | 06/10/05 | Nastech to Present at Morgan Stanley Small Cap Executive Conference| BOTHELL, Wash., June 10, 2005 /PRNewswire-FirstCall via COMTEX/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) will be presenting at the Morgan Stanley Small Cap
Executive Conference on Tuesday, June 14, 2005 at 2:45 p.m. Eastern Time at
The Ritz-Carlton New York, Battery Park in New York City. Gordon Brandt,
M.D., Executive Vice President, Clinical Research and Medical Affairs of
Nastech, will provide a corporate overview, including a review of the
Company's product development pr... |
| | | 06/06/05 | Nastech to Present at Pacific Growth Equities Life Sciences Conference| BOTHELL, Wash., June 6 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) will be presenting at the Pacific Growth Equities
Life Sciences Conference on Wednesday, June 8, 2005 at 7:30 a.m. Pacific Time
at the InterContinental Mark Hopkins Hotel in San Francisco, CA. Gordon
Brandt, M.D., Executive Vice President, Clinical Research and Medical Affairs
of Nastech, will provide a corporate overview, including a review of the
Company's product development programs.
... |
| | | 05/31/05 | Nastech Awarded Patent Covering Treatment and Prevention of Breast Cancer| BOTHELL, Wash., May 31 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) today announced that it has been awarded U.S.
patent No. 6,894,026, entitled, "Long-acting Oxytocin Analogues for the
Treatment and Prevention of Breast Cancer and Psychiatric Disorders." The
patent covers methods for the treatment of breast cancer by the administration
of long-acting analogues of the peptide hormone oxytocin. The patent contains
11 claims and the inventor is Steven C. Qua... |
| | | 05/26/05 | Nastech to Present at Friedman Billings Ramsey 9th Annual Growth Conference| BOTHELL, Wash., May 26 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) will be presenting at the Friedman Billings Ramsey
9th Annual Growth Conference on Thursday, June 2, 2005 at 11:40 a.m. Eastern
Time at the Millennium Broadway Hotel in New York City. Gordon Brandt, M.D.,
Executive Vice President, Clinical Research and Medical Affairs of Nastech,
will provide a corporate overview, including a review of the Company's product
development programs.
To a... |
| | | 05/26/05 | Nastech Receives Innovative Business Award at the 2005 Eastside Business Awards| BOTHELL, Wash., May 26 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) announced today that it was awarded the
"Innovative Business Award" in the 2005 Eastside Business Awards, sponsored by
the Bellevue, Washington Chamber of Commerce. Businesses competing for this
award were evaluated on their demonstration of innovation and creativity in
developing a product or service.
"We are privileged to have been recognized by the Bellevue Chamber of
Commerce with... |
| | | 05/23/05 | Steven C. Quay, M.D., Ph.D., Chairman, President and Chief Executive Officer of Nastech, Named a Finalist for Ernst & Young Entrepreneur Of The Year(R) 2005 Award| BOTHELL, Wash., May 23 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) announced today that Steven C. Quay, M.D., Ph.D.,
Chairman, President and Chief Executive Officer of Nastech, has been named a
finalist by Ernst & Young LLP for the professional services firm's
Entrepreneur Of The Year(R) 2005 Awards in the Pacific Northwest. Dr. Quay
was selected from 40 nominations in the Pacific Northwest by a panel of
independent judges comprised of area leaders from bu... |
| | | 05/18/05 | Nastech to Present at UBS Global Pharmaceuticals and Needham & Company Fourth Annual Biotechnology Conferences| BOTHELL, Wash., May 18 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) announced today that Steven C. Quay, M.D., Ph.D.,
Chairman, President and Chief Executive Officer of Nastech, will be presenting
at the UBS Global Pharmaceuticals Conference, taking place May 23-24 at the
Grand Hyatt in New York, and the Needham & Co. Fourth Annual Biotechnology
Conference, taking place May 25-26 at the New York Palace Hotel in New York.
UBS Global Pharmaceuticals Co... |
| | | 05/09/05 | Nastech Announces First Quarter 2005 Financial Results| BOTHELL, Wash., May 9, 2005 /PRNewswire-FirstCall via COMTEX/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) today reported financial results for the quarter
ended March 31, 2005.
Revenue for the quarter ended March 31, 2005 was $3.3 million, compared to
revenue of $0.1 million for the quarter ended March 31, 2004. The increase in
revenue reflects a $2.0 million milestone payment received upon FDA approval
of Nascobal(R) spray, and growth in the number of revenue generating
co... |
| | | 04/27/05 | Nastech to Release First Quarter Financial Results and Host Webcast on Monday, May 9, 2005| BOTHELL, Wash., April 27, 2005 /PRNewswire-FirstCall via COMTEX/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) announced today that its first quarter financial
results will be released on Monday, May 9, 2005 after the Nasdaq National
Market System closes. Management will host a conference call with investors
and financial analysts to discuss these results and to provide an update to
its clinical pipeline at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time).
To participate in the ... |
| | | 04/19/05 | Nastech to Present at the 4th Annual Invest Northwest Conference| BOTHELL, Wash., April 19 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) will be presenting at the 4th Annual Invest
Northwest conference on Tuesday, April 26, 2005 at 2:20 p.m. Pacific Time
(5:20 p.m. Eastern Time) at the Bell Harbor International Conference Center in
Seattle, WA. Steven C. Quay, M.D., Ph.D., Chairman, President and Chief
Executive Officer of Nastech will provide a corporate overview, including a
review of the Company's product development pr... |
| | | 04/12/05 | Nastech Announces Nomination of Susan B. Bayh, J.D., and Alexander D. Cross, Ph.D., to Its Board of Directors| BOTHELL, Wash., April 12, 2005 /PRNewswire-FirstCall via COMTEX/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) announced today that it has nominated Susan B.
Bayh, J.D., and Alexander D. Cross, Ph.D., to its board of directors.
Mrs. Bayh currently serves on the board of directors of Curis, Inc., a
therapeutic drug development company, Dendreon Corporation, a therapeutic drug
development company, Dyax Corp., a biopharmaceutical company, Emmis
Communications, a diversified media ... |
| | | 04/05/05 | Nastech Presents Promising In Vivo Research Findings with RNAi-Based Therapeutics for Rheumatoid Arthritis| Data Presented in Late-Breaking Session at ASBMB Meeting
BOTHELL, Wash., April 5 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) today announced the presentation of data
demonstrating the successful preclinical, in vivo use of an RNA interference
(RNAi)-based therapeutic drug directed against the expression of human tumor
necrosis factor alpha (H-TNF-alpha), a protein that is over-expressed in
rheumatoid arthritis and plays an important role in disease pa... |
| | | 04/05/05 | Nastech Announces RNAi Therapeutics-Based Rheumatoid Arthritis Clinical Study Collaboration| BOTHELL, Wash., April 5 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) today announced that it has entered into a
clinical research collaboration with the Mayo Clinic to evaluate Nastech's RNA
interference (RNAi)-based therapeutic formulations in immune cells from
patients with rheumatoid arthritis (RA) for the purpose of selecting a
candidate for preclinical and clinical development. Data demonstrating the
successful preclinical, in vivo use of an RNA interf... |
| | | 03/29/05 | Nastech to Highlight Therapeutic RNA Interference Program for Rheumatoid Arthritis, and Tight Junction and Phage Display Research Programs at 2005 American Society of Biochemistry and Molecular Biology Annual Meeting| BOTHELL, Wash., March 29, 2005 /PRNewswire-FirstCall via COMTEX/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) today announced that data from its therapeutic RNA
interference program for rheumatoid arthritis and tight junction technology
and phage display research programs will be presented during the 2005 American
Society for Biochemistry and Molecular Biology Annual Meeting to be held April
2-6 in San Diego, Calif.
"Nastech has a directed research program that supports our co... |
| | | 03/02/05 | Nastech Announces 2004 Financial Results| BOTHELL, Wash., March 2 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) today reported financial results for the quarter
and year ended December 31, 2004.
Nastech ended 2004 with $74.5 million in cash, cash equivalents and
short-term investments compared to $25.1 million at December 31, 2003. In
December 2004 we completed the sale of 4.25 million shares of our common stock
at $13.50 per share and received net proceeds after expenses of approximately
$53... |
| | | 02/23/05 | Nastech to Release 2004 Financial Results and Host Webcast on Wednesday, March 2, 2005| BOTHELL, Wash., Feb. 23 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) announced today that its fiscal 2004 financial
results will be released on Wednesday, March 2, 2005 before the Nasdaq
National Market System opens. Management will host a conference call with
investors and financial analysts to discuss these results and to provide an
update to its clinical pipeline at 11:00 a.m. Eastern Time (8:00 a.m. Pacific
Time).
To participate in the live confe... |
| | | 02/15/05 | Nastech Announces New Presentation Time Slot for Citigroup Smith Barney Conference| BOTHELL, Wash., Feb 15, 2005 /PRNewswire-FirstCall via COMTEX/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) announced today that its presentation time slot at
the Citigroup Smith Barney Small and Mid Cap Conference at the Four Seasons
Hotel, Mandalay Bay, Las Vegas, Nevada, on February 17, 2005, has been changed
to 3:05 p.m. Pacific Time (6:05 p.m. Eastern Time).
The presentation will be available via webcast at the following URL
http://www.veracast.com/webcasts/sbcitigroup/sm... |
| | | 02/10/05 | Nastech to Present at Citigroup Smith Barney Conference February 17, 2005| BOTHELL, Wash., Feb. 10 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) announced that Steven C. Quay, M.D., Ph.D.,
chairman, president and chief executive officer, will be presenting at the
Citigroup Smith Barney Small and Mid Cap Conference at the Four Seasons Hotel,
Mandalay Bay, Las Vegas, Nevada, at 3:45 p.m. Pacific Time on February 17,
2005.
"We are pleased to have the opportunity to provide an update to the market
and set expectations for near-te... |
| | | 02/01/05 | Nastech Receives FDA Approval for Nascobal Nasal Spray for Malabsorptive and Diet-Related B12 Deficiencies| - Triggers a $2.0 MM Milestone Payment to Nastech - BOTHELL, Wash., Feb 01, 2005 /PRNewswire-FirstCall via COMTEX/ -- Nastech Pharmaceutical
Company Inc. ("Nastech") (Nasdaq: NSTK), a leader in drug delivery technology,
announced the approval by the U.S. Food and Drug Administration (FDA) of
Nascobal(R) (Cyanocobalamin, USP) Nasal Spray for the treatment of vitamin B12
(cyanocobalamin) deficiency in patients with pernicious anemia, Crohn's
Disease, HIV/AIDS, and multiple sclerosis.
Na... |
| | | 01/26/05 | Nastech Pharmaceutical Company Inc. Announces Initiation of Clinical Trial for Investigational PYY3-36 Nasal Spray Under Co-Development and Co-Promotion Alliance with Merck & Co., Inc.| BOTHELL, Wash., Jan. 26 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) announced today that its partner, Merck & Co.,
Inc., has initiated a Phase I study for PYY3-36 Nasal Spray for the treatment
of obesity.
"This study being conducted by Merck builds upon Nastech's PYY clinical
program. To date, 63 subjects have received more than 900 doses of intranasal
PYY, a synthetic form of the naturally-occurring peptide," said Gordon Brandt,
M.D., Executive Vice... |
| | | 01/24/05 | Nastech to Present at Drug Delivery Partnerships Conference| BOTHELL, Wash., Jan 24, 2005 /PRNewswire-FirstCall via COMTEX/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) announced that Gordon Brandt, M.D., Executive Vice
President, Clinical Research and Medical Affairs, is presenting at the Drug
Delivery Partnerships conference in San Diego, California. Dr. Brandt's
presentation, entitled, "Creating Solutions for Enhanced Peptide and Protein
Delivery through Nastech's Drug Delivery System," is scheduled for Wednesday,
January 26 at 2:45 p.m... |
| | | 01/14/05 | Nastech to Present at Two Investor Conferences in February 2005|
Citigroup Smith Barney Small/Mid Cap Conference, February 16 and 17, Las
Vegas, NV, and BIO CEO & Investor Conference, February 23 and 24, New York
City, NY
BOTHELL, Wash., Jan. 14 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. ("Nastech") (Nasdaq: NSTK) today announced that Steven C. Quay,
M.D., Ph.D., chairman, president and chief executive officer will be
presenting at the following upcoming investor conferences:
Ci... |
| |
|
|
|
